Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

Clinical trial NCT06632951 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06632951
Sponsor: AbbVie
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Urothelial Carcinoma

Start date: 2025-01-20
Primary completion: 2027-03-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.